| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We have developed a new single-cell analysis platform that can identify mutations with high sensitivity for the analysis of refractory clones in intratumor heterogeneity, which is a major factor in the therapy resistance of hematological malignancies. Using this method, hematopoietic progenitors derived from the bone marrow of healthy individuals or patients with hematological malignancies were analyzed. We found that apparently normal hematopoietic progenitors show aberrant expression profiles compared to normal cells in healthy controls without driver mutations. These results suggest that a favorable environment for the clone is important for their expansion and was considered to be an important finding for the realization of a new therapeutic intervention.
|
